The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Novel Device To Improve Renal Blood Flow In Cardiorenal Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$198,900.00
Summary
The aim of this project is to assist in the development of a novel device to treat poor delivery of blood to the kidneys in conditions such as heart muscle weakness (chronic heart failure, CHF). Specifically we aim to build a prototype and test the device in a relevant animal model of CHF. Chronic heart failure is a major public health problem affecting >10% of the adult population over the age of 60 years. It is associated with high morbidity, mortality, frequent hospitalisation and major co ....The aim of this project is to assist in the development of a novel device to treat poor delivery of blood to the kidneys in conditions such as heart muscle weakness (chronic heart failure, CHF). Specifically we aim to build a prototype and test the device in a relevant animal model of CHF. Chronic heart failure is a major public health problem affecting >10% of the adult population over the age of 60 years. It is associated with high morbidity, mortality, frequent hospitalisation and major cost burden on the public health system. Weak heart muscle results in poor delivery of blood to the kidneys. Poor delivery to the kidneys activates circulating hormones which in turn further impair cardiac function by adverse effects on the heart. We have developed and patented a novel catheter based system for improvement of renal function via a purpose built device. Proof-of-concept studies have shown that the device should improve kidney blood flow in the setting of CHF. Given the huge public health problem of heart failure and the importance of the kidney in this setting, the commercial potential for a simple device that can be positioned via a catheter-based approach, permanently implanted is large. The device is currently being constructed by the Monash University Department of Engineering where expertise exists with regard to biomedical devices and materials engineering. A series of proof-of-concept studies will then be performed in sheep, as the vasculature of the sheep roughly approximates the dimensions of man. Sheep with CHF will have the device inserted percutaneously into the aorta. Measurements will be made of renal artery flow, relevant circulatory hormones and ultrasound of the heart at baseline (pre-deployment) and following deployment. We believe the above studies (should they be successful) will be sufficient to constitute definitive proof-of-concept and thus allow the device to be commercialised, most likely by a licensing arrangement with a device company.Read moreRead less
UTILITY OF NOVEL BIOMARKERS IN THE PREDICTION OF MAJOR COMPLICATIONS OF TYPE II DIABETES MELLITUS
Funder
National Health and Medical Research Council
Funding Amount
$510,639.00
Summary
Diabetes is increasingly common. It can cause a variety of complications, the most serious being heart and kidney disease. The reasons why some patients develop such complications are not fully understood so it is difficult to predict who will be affected. The current project will use samples from a large international study of patients with diabetes to assess whether levels of specific markers in the blood help to predict major complications and clarify why they occur.
Protective Role Of The Depressor Arm Of The Renin-angiotensin System During Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$633,384.00
Summary
The motivation for unveiling the normal hormonal and molecular mechanisms involved in the extraordinary vasodilatation associated with pregnancy is that understanding these fundamental processes may provide novel insights into the pathophysiology of preeclampsia and intrauterine growth restriction, as well as potential therapeutic strategies for not only the treatment of these pregnancy specific conditions but also cardiovascular and renal diseases in non-pregnant women and men.
Renal AT2R Are A Therapeutic Target For The Treatment Of Hypertension In Women
Funder
National Health and Medical Research Council
Funding Amount
$605,939.00
Summary
Being female is associated with better renal function, resistenace to renal injury and hypertension, but it is not understood why. Our work demonstrates that women have more angiotensin type 2 receptors (AT2R) in the kidney then men. In men AT2R have been suggested to protect against hypertension and renal damage. We predict that the effects of AT2R stimulation will be greater in women and therefore the protective benefits greater.
Catheter Based Renal Denervation To Improve Outcomes In Congestive Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$619,194.00
Summary
In heart failure there is a large increase in sympathetic nerve activity that is detrimental to patient outcome, but the factors causing this increased activity are not well defined. There is evidence that renal nerves play a significant role. A novel catheter based technique allows silencing of these nerves. We will test whether this novel technique has the potential to improve the outcomes for patients with heart failure.
Associate Professor Kate Denton is an internationally recognised cardiovascular researcher. A focus of Dr Denton’s research is to find out why women do not respond to current treatments as well as men, and how factors in pregnancy (nutrition, stress, alcohol) drive the development of cardiovascular disease in offspring. Dr Denton is also leading research to understand why a new high blood pressure treatment (blocking nerves to the kidney) is proving more effective than expected.
Renal Sympathetic Denervation As An Adjunct To Catheter-based Ventricular Tachycardia Abaltion
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
The most common cause of sudden death is lethal heart rhythms. Despite medications and medical procedures, many patients still suffer from these life-threatening rhythms. Treatment of the nerves around the kidneys may alter the production of hormones that contribute to these rhythms which could have a significant impact on these patients.
Renal Artery Denervation Performed With Noncontact Circumferential Endovascular Ablation Using A Novel Microwave Catheter
Funder
National Health and Medical Research Council
Funding Amount
$90,967.00
Summary
High blood pressure is a common medical condition leading to death and disability. Some people with high blood pressure do not respond to medical treatment due to abnormal signals from the kidneys that tell the body to increase the blood pressure. We have designed a microwave catheter that can be placed inside the kidney artery and used to heat the kidney nerves around it to stop the relay of these messages. This will lower blood pressure for people who cannot control it with medications alone.
Resistant Hypertension: Causes, Consequences, And Novel Therapeutic Approaches
Funder
National Health and Medical Research Council
Funding Amount
$713,517.00
Summary
Two thirds of all strokes and half of all coronary artery disease world-wide can be attributed to uncontrolled blood pressure. Patients with resistant hypertension are at specifically high risk. While the exact reasons remain obscure, work from my group suggests that sympathetic nervous system activation represents a common pathway. Based on these findings the ultimate goal of my research program is to develop novel and more effective treatment strategies for resistant hypertension.
Enhancing Erythropoietin Therapy In Ischaemia-reperfusion Injury Of Heart And Kidney
Funder
National Health and Medical Research Council
Funding Amount
$361,021.00
Summary
Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.